Compounded tirzepatide vs Mounjaro vs Zepbound: a 2026 comparison
Mounjaro, Zepbound, and compounded tirzepatide all use the same active ingredient: tirzepatide. The molecule is identical. The differences come down to FDA-approved indication, branded versus compounded pricing, dosing schedule, and the carrier formulation paired with the active. This guide compares all three honestly, including the gap between Eli Lilly's once-weekly schedule and the twice-weekly protocol used by most compounding telehealth clinics.
7 min read · Updated September 8, 2026
Medically reviewed by Dr. Jonathan Snipes, MD and Kim Callender, NP, FNP-BC. Last reviewed September 8, 2026.The short answer
Mounjaro and Zepbound are Eli Lilly’s two FDA-approved tirzepatide products. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management. Both deliver the same molecule at the same strengths through identical pre-filled pens. Compounded tirzepatide dispensed by a U.S. 503A pharmacy uses the same active ingredient with a different carrier (B-12 or glycine plus B-6) and a different dosing protocol chosen for tolerability. Trial-grade efficacy data on tirzepatide applies to all three because the molecule is the same.
Side-by-side comparison
| Mounjaro | Zepbound | Compounded tirzepatide (RxPepsDirect) | |
|---|---|---|---|
| Manufacturer | Eli Lilly | Eli Lilly | Optimal Balance Pharmacy |
| FDA indication | Type 2 diabetes | Chronic weight management | Compounded under 503A patient-specific |
| Active ingredient | Tirzepatide | Tirzepatide | Tirzepatide |
| Carrier | Lilly excipients | Lilly excipients | B-12 or glycine + B-6 |
| Standard dosing | 2.5 mg once weekly | 2.5 mg once weekly | 1.5 mg twice weekly (3 mg/wk) |
| Form | Pre-filled pen | Pre-filled pen | Pre-reconstituted vial + insulin syringe |
| Trial weight loss | SURMOUNT-1: 15-22% over 72 wk | SURMOUNT-1: 15-22% over 72 wk | Same molecule; same trial evidence applies |
| Starter price (cash) | ~$1,087/mo list; no self-pay program | $299/mo (2.5 mg) self-pay via LillyDirect; list ~$1,087 | From $45 / 12 mg + $39 visit ($84) |
The active ingredient is identical
Tirzepatide is a single chemical entity: a 39-amino acid peptide that activates both the GIP and GLP-1 receptors. The molecule delivered by Mounjaro, Zepbound, and compounded tirzepatide is chemically the same. Pharmacokinetics (absorption, distribution, half-life, clearance) are identical. The receptor binding affinity is identical. The downstream metabolic effects (appetite suppression, slowed gastric emptying, insulin sensitization) are identical.
What differs is the package around the molecule: branded products ship in a pre-filled pen with proprietary excipients; compounded products ship in a sterile vial co-formulated with B-12 or glycine as a carrier. Carriers do not change the GIP or GLP-1 receptor binding. They are inert with respect to weight-loss pharmacology.
Why the dosing schedule differs
Eli Lilly’s prescribing information specifies 2.5 mg once weekly as the starting dose for both Mounjaro and Zepbound, titrating up every 4 weeks to a target of 5 mg, 10 mg, or 15 mg per week. Compounded telehealth clinics, including RxPepsDirect, typically prescribe a 1.5 mg twice-weekly protocol (3 mg per week total) instead of 2.5 mg once-weekly.
The rationale is pharmacokinetic. Tirzepatide has a roughly 120-hour half-life. Once-weekly dosing produces a peak plasma concentration 8 to 72 hours after injection, which is when GI side effects (nausea, fatigue, loose stool) cluster most strongly. Splitting the same weekly dose into two injections flattens the AUC curve and lowers the peak. Patients on the split-dose protocol generally report milder titration nausea than patients on the standard once-weekly schedule. No head-to-head RCT has compared the two protocols directly; the support for split dosing comes from PK modeling and accumulated clinical experience.
Why the prices differ
Branded tirzepatide still lists at about $1,087 a month, but the cash price most self-pay patients actually pay is lower than it was a year ago. Since December 1, 2025, Eli Lilly has sold Zepbound single-dose vials, and now the KwikPen, through LillyDirect and TrumpRx at $299 a month for 2.5 mg, $399 for 5 mg, and $449 for 7.5 mg through 15 mg (the $449 tier requires refilling within 45 days; otherwise it is $499 to $699). Mounjaro, the diabetes label of the same molecule, has no self-pay program. Novo Nordisk’s Wegovy pens are $199 a month for the first two fills and $349 after that, and the new GLP-1 pills (the Wegovy pill and Lilly’s Foundayo) run $149 to $349. Those prices still carry the cost of phase-three trials, FDA approval, marketing, distribution, and margin to the manufacturer. Insurance coverage varies and most commercial plans cover at least one of the two tirzepatide products with prior authorization.
Compounded tirzepatide goes through a 503A pharmacy that prices closer to the raw active-ingredient cost plus sterile-compounding labor. RxPepsDirect’s 12 mg starter vial of Tirzepatide/B12 lists at $45 from Optimal Balance Pharmacy with a flat $39 medical visit fee. RxPepsDirect does not mark up the medication; the $39 covers the licensed nurse practitioner or physician assistant who reviews your intake and writes the prescription. At the starter dose that is $84 all-in against $299 for the cheapest Zepbound vial; at the top of the ladder a 66 mg vial is $247.50 against $449.
When each option makes sense
Mounjaro or Zepbound is the right choice for patients whose insurance covers one of them, who want the FDA-approved branded product, and who are comfortable on the standard once-weekly schedule. The pre-filled pen design is preferred by some patients over a vial-and-syringe workflow.
Compounded tirzepatide is the right choice for patients whose insurance does not cover branded GLP-1s, who want a lower cash-pay price, who prefer the smoother twice-weekly tolerability profile, or who have a documented B-12 sensitivity and need the glycine variant. RxPepsDirect’s Tirzepatide/B12 and Tirzepatide/Glycine product pages have the full per-vial pricing ladder. To see how it compares with other services, read our ranking of the best compounded tirzepatide telehealth services.
Bottom line
Same molecule, three packages. Branded products carry FDA approval and pen-design premium pricing. Compounded versions go through a 503A pharmacy at near-wholesale and ship pre-reconstituted in a vial. Trial efficacy data applies to all three because the molecule is identical. The dosing protocol, carrier, and price are where the practical differences live.
Continue reading